Get Retatrutide Online in Wisconsin | OmniRx Health
Medical Weight Loss Treatment in Wisconsin
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Wisconsin
Wisconsin's hardworking people deserve healthcare that fits their lifestyle. From the breweries of Milwaukee to the government center of Madison, the manufacturing towns along Lake Michigan to the dairy farms of the Driftless Region, OmniRx Health serves all of America's Dairyland. Our telehealth platform understands Wisconsin values—no-nonsense, quality care delivered efficiently, whether you're in a major city or a small town.
OmniRx Health providers are licensed by the Wisconsin Medical Examining Board for comprehensive statewide telehealth services.
Wisconsin pharmacies in Milwaukee, Madison, Green Bay, and throughout the state provide prescription services with reliable delivery.
Wisconsin has telehealth laws that support virtual care delivery while maintaining quality standards for patient safety.
Wisconsin insurers cover telehealth services, with ongoing efforts to expand access and ensure fair reimbursement.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Wisconsin?
- Yes, telehealth is legal in Wisconsin. The state supports virtual healthcare delivery, allowing licensed providers to offer consultations, prescriptions, and ongoing care.
- Can northern Wisconsin residents use telehealth?
- Telehealth is essential for northern Wisconsin, where distances to specialists can be significant. Our platform brings care to the Northwoods, Door County, and beyond.
- Does Wisconsin BadgerCare cover telehealth?
- Yes, Wisconsin's BadgerCare Plus (Medicaid) covers telehealth services for eligible members. Virtual visits are an approved method of care delivery.